Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVAX stock appears to be a decent wager in the vaccine sweepstakes despite recent volatility and some insider selling.
The post Novavax Is Worth a Bet in the Vaccine Race appeared first on InvestorPlace.

Novavax Is Worth a Bet in the Vaccine Race

The key variable in this race is not the phase 3 trial, but which company has enough positive data for an Emergency Use Authorization.

Why Novavax's Coronavirus Vaccine Might Be First to Market

Novavax stock has been a top performer in 2020, but concern it may lose the race for the first Covid-19 vaccine has NVAX stock slumping.
The post Novavax’s Slump Is a Huge Buying Opportunity appeared first on InvestorPlace.

Novavax’s Slump Is a Huge Buying Opportunity

Fastly

Guardant Health Inc

You don't need a huge initial investment with massive growth opportunities from these stocks.

Investing $3,000 in These 3 Stocks Could Make You a Fortune Over the Next Decade

Co-Diagnostics

Ichor Hlds

CarParts.com, Inc.

Textainer Group Holdings Limited

Tata Motors

Unisys

VirnetX

XBiotech

These are the small cap stocks with the best value, fastest growth, and most momentum for September.

Top Small Cap Stocks for September 2020

Novavax, Inc. (NASDAQ: NVAX), which has seen its stock plunge hard in recent weeks, was the subject  December Regulatory Filing For Novavax?

Novavax CEO Eyes December Regulatory Filing For Coronavirus Vaccine Candidate

Biotech firm Novavax reportedly is targeting December to apply for U.S. approval of its coronavirus vaccine candidate, as its Phase 2 clinical trails ramp up.

Novavax Reportedly Targets December For U.S. Coronavirus Vaccine Application

Altimmune

iBio

Vaxart

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus.

These 5 Healthcare Stocks Are the Biggest Winners in 2020

Having two major vaccine candidates in its repertoire makes NVAX stock an attractive investment, but a pullback is imperative.
The post Wait for a Pullback Before Investing in Novavax appeared first on InvestorPlace.

Wait for a Pullback Before Investing in Novavax

Invitae

SPDR S&P Biotech ETF

Nearby support levels and well-defined risk/reward setups will likely make the biotech sector a favorite of active traders for the rest of 2020.

3 Charts Suggest Biotech Stocks Are Headed Higher

Vaccine approval certainly can drive NVAX stock back to new highs after a recent pullback. But risks go beyond vaccine development.

3 Key Questions to Ask Before Buying Novavax

AstraZeneca

Pfizer

COVID-19 vaccine makers are lobbying the European Union for protection against lawsuits should problems arise with new therapies, the Financial Times reported Tuesday.

AstraZeneca, Novavax, Pfizer, Others Lobby EU For Legal Protection Against COVID-19 Vaccine Liabilities: FT

Novavax achieved positive preliminary data in patients with COVID-19.

Novavax Continues Progress: Latest COVID-19 Data Shows Encouraging Signs Of Advancement

Novavax, Inc. (NASDAQ: NVAX) stock has fallen significantly from its Aug. 5 peak of $189.40, which was reached on the back of positive interim Phase 1 data for its coronavirus vaccine candidate NVX-CoV2373.

Novavax Shares Down 40% From Early August Peak: What's Behind The Weakness?

Novavax (NVAX) starts enrolling in the phase II portion of its COVID-19 vaccine study, which is testing the immunogenicity and safety of its candidate NVX-CoV2373 in the United States and Australia.

Novavax Begins Enrollment in Phase II Coronavirus Vaccine Study

Monday's sell-off continued into Tuesday.

Why Novavax Stock Is Sinking Again Today

Yes, the biotech's insiders are selling. No, there's nothing to worry about.

Here's How Much Stock Key Novavax Insiders Just Sold

The biotech moves one step closer to hopefully launching NVX-CoV2373.

Novavax Starts Phase 2 Coronavirus Vaccine Clinical Trial

Inovio Pharmaceuticals

Moderna

Regeneron Pharmaceuticals

Sanofi

Sorrento Therapeutics Inc

These are the top stocks to buy based on the 2020 U.S. presidential election, with new stock picks updated daily from the sharpest investing minds in the business.

Investing for the Election: 6 Vaccine Stocks to Buy for Operation Warp Speed

Even a vaccine that's 50% effective with some side effects would be a game changer. The Trump Administration is throwing billions into that hope and investors are seeing big profits.

6 Hot Coronavirus Stocks Moving At “Warp Speed”

Novavax, Inc. (NASDAQ: NVAX) has announced another milestone event in the development of its coronavirus vaccine, codenamed NVX-CoV2373.

Novavax Starts Phase 2 Coronavirus Vaccine Trial, Expects Interim Readout In Q4

Is  (NVAX) Outperforming Other Medical Stocks This Year?

Is Novavax (NVAX) Outperforming Other Medical Stocks This Year?

Heat Biologics

Reports of an early approval for AstraZeneca's COVID-19 vaccine are sending these three stocks lower today.

Why Heat Biologics, Inovio Pharmaceuticals, and Novavax Are Getting Clobbered Today

Aileron Therapeutics

Celldex Therapeutics

Emergent BioSolutions

Horizon Pharma

Here we discuss five biotech companies recording impressive growth so far in 2020.

5 Biotech Stocks Up More Than 100% This Year So Far

GAITHERSBURG, Md., Aug.  24, 2020  (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the first volunteers have been enrolled in the Phase 2 portion of its ongoing clinical trial to evaluate the immunogenicity and safety of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate. The Phase 2 clinical trial expands on the age range of the Phase 1 portion by including older adults 60-84 years of age as approximately 50 percent of the trial’s population. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.

News for Novavax Stock (NVAX)